Institution
University of Groningen
Education•Groningen, Groningen, Netherlands•
About: University of Groningen is a education organization based out in Groningen, Groningen, Netherlands. It is known for research contribution in the topics: Population & Poison control. The organization has 36346 authors who have published 69116 publications receiving 2940370 citations. The organization is also known as: Rijksuniversiteit Groningen & RUG.
Papers published on a yearly basis
Papers
More filters
••
TL;DR: Interferon beta-1b 250 μg subcutaneously every other day delayed conversion to clinically definite multiple sclerosis, and should be considered as a therapeutic option in patients presenting with a first clinical event suggestive of multiple sclerosis.
Abstract: Objective: To assess efficacy, safety, and tolerability of every-other-day interferon beta-1b treatment in patients with a first clinical event suggestive of multiple sclerosis (MS) (clinically isolated syndrome). Methods: We conducted a multicenter, randomized, double-blind, placebo-controlled trial. Patients with a first clinical demyelinating event and at least two clinically silent brain MRI lesions were randomized to interferon beta-1b (IFNB-1b) 250 μg subcutaneously (SC) every other day (EOD) (n = 292) or placebo (n = 176), until clinically definite MS (CDMS) was diagnosed or they had been followed for 24 months. Results: After 2 years, 45% of placebo patients had converted to CDMS (Kaplan-Meier estimate; primary outcome measure) and 85% fulfilled the McDonald criteria (co-primary outcome measure). Overall interferon beta-1b delayed the time to diagnosis of CDMS ( p p Conclusions: Interferon beta-1b 250 μg subcutaneously every other day delayed conversion to clinically definite multiple sclerosis, and should be considered as a therapeutic option in patients presenting with a first clinical event suggestive of multiple sclerosis.
578 citations
••
TL;DR: Strain imaging detects impaired systolic function despite preserved global LVEF inHFpEF that may contribute to the pathophysiology of the HFpEF syndrome.
577 citations
••
28 Aug 2001TL;DR: The authors provide a framework of terminology and concepts regarding variability and present three recurring patterns of variability, which they suggest a method for managing variability in software product lines.
Abstract: The authors discuss the notion of variability. We have experienced that this concept has so far been underdefined, although we have observed that variability techniques become increasingly important. A clear indication of this trend is the recent emergence of software product lines. Software product lines are large, industrial software systems intended to specialize into specific software products. The authors provide a framework of terminology and concepts regarding variability. In addition, they present three recurring patterns of variability. Finally, they suggest a method for managing variability in software product lines.
577 citations
••
TL;DR: Calcium was shown to enhance the tendency of SLB formation for negatively charged and zwitterionic vesicles, and the role of vesicle-support, interbilayer, and intrabilayer interactions in the formation of SLBs is discussed.
574 citations
••
TL;DR: In patients with severe ANCA-associated vasculitis, a single course of rituximab was as effective as continuous conventional immunosuppressive therapy for the induction and maintenance of remissions over the course of 18 months.
Abstract: A total of 197 patients were enrolled. As reported previously, 64% of the patients in the rituximab group, as compared with 53% of the patients in the cyclophosphamide– azathioprine group, had a complete remission by 6 months. At 12 and 18 months, 48% and 39%, respectively, of the patients in the rituximab group had maintained the complete remissions, as compared with 39% and 33%, respectively, in the com parison group. Rituximab met the prespecified criteria for noninferiority (P<0.001, with a noninferiority margin of 20%). There was no significant difference between the groups in any efficacy measure, including the duration of complete remission and the frequency or severity of relapses. Among the 101 patients who had relapsing disease at baseline, rituximab was superior to conventional immunosuppression at 6 months (P = 0.01) and at 12 months (P = 0.009) but not at 18 months (P = 0.06), at which time most patients in the rituximab group had reconstituted B cells. There was no significant between-group difference in adverse events. Conclusions In patients with severe ANCA-associated vasculitis, a single course of rituximab was as effective as continuous conventional immunosuppressive therapy for the induction and maintenance of remissions over the course of 18 months. (Funded by the Na tional Institute of Allergy and Infectious Diseases and others; RAVE ClinicalTrials.gov number, NCT00104299.)
573 citations
Authors
Showing all 36692 results
Name | H-index | Papers | Citations |
---|---|---|---|
Ronald C. Kessler | 274 | 1332 | 328983 |
Nicholas J. Wareham | 212 | 1657 | 204896 |
André G. Uitterlinden | 199 | 1229 | 156747 |
Lei Jiang | 170 | 2244 | 135205 |
Brenda W.J.H. Penninx | 170 | 1139 | 119082 |
Richard H. Friend | 169 | 1182 | 140032 |
Panos Deloukas | 162 | 410 | 154018 |
Jerome I. Rotter | 156 | 1071 | 116296 |
Christopher M. Dobson | 150 | 1008 | 105475 |
Dirk Inzé | 149 | 647 | 74468 |
Scott T. Weiss | 147 | 1025 | 74742 |
Dieter Lutz | 139 | 671 | 67414 |
Wilmar B. Schaufeli | 137 | 513 | 95718 |
Cisca Wijmenga | 136 | 668 | 86572 |
Arnold B. Bakker | 135 | 506 | 103778 |